UNLIMITED TURBO SHORT - ROCHE GS Share Price

Certificat

DE000PD42704

Delayed Deutsche Boerse AG 15:21:07 13/06/2024 BST
9.7 EUR -2.41% Intraday chart for UNLIMITED TURBO SHORT - ROCHE GS
Current month-10.45%
1 month-14.38%
Date Price Change
13/06/24 9.7 -2.41%
12/06/24 9.94 -2.55%
11/06/24 10.2 -0.58%
10/06/24 10.26 +3.85%
07/06/24 9.88 -4.54%

Delayed Quote Deutsche Boerse AG

Last update June 13, 2024 at 03:21 pm

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellPUT
Underlying ROCHE HOLDING AG
IssuerLogo Issuer BNP Paribas BNP Paribas
WKN PD4270
ISINDE000PD42704
Date issued 22/04/2022
Strike 337.2 CHF
Maturity Unlimited
Parity 10 : 1
Emission price 0.89
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 13.53
Lowest since issue 1.02

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
243.5 CHF
Average target price
277.5 CHF
Spread / Average Target
+13.97%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW